This result suggested that this APOL3 stop-gain variant may have an epistatic interaction with APOL1 G1/G2 and increases risk of CKD most prominently in monoallelic carriers for either the APOL1 G1 or G2 allele. This evidence concerns the gene APOL1 and chronic kidney disease.